Join the Adzenys ER group to help and get support from people like you.
Adzenys ER News
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
WEDNESDAY, July 2, 2025 – The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain...
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
WEDNESDAY, July 2, 2025 – Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations...
Prescribing ADHD Meds by Telehealth Does Not Alter Risk for Substance Use Disorder Overall
TUESDAY, June 17, 2025 – Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for substance use disorder...
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 – Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to...
ADHD Drugs Generally Safe For Heart Health, Review Says
MONDAY, April 14, 2025 – Worried about taking the ADHD meds you’ve been prescribed because they might harm your heart health? There’s no need to fret, according to a new evidence review. ADHD med...
Rx Amphetamine Use Linked to Increased Odds of Psychosis, Mania
TUESDAY, Sept. 17, 2024 – Past-month prescription amphetamine use is associated with increased odds of psychosis and mania, with increased odds for high doses (>30 mg dextroamphetamine equivalents),...
Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER (amphetamine) Extended-Release Oral Suspension for ADHD
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) – Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD)